Yesterday, DNAPrint Genomics (DNAG) announced in a Press Release, its launching of clinical studies for Post Operative Nausea and Vomiting (PONV). Studies show that the potential side affects of anesthesia, is one of the major concerns of patients going into surgery and DNAG can now screen patients to calculate their probability of having negative side affects and with new PONV testing, help doctors administer alternative methods. DNAG’s cutting edge technology is finding a wide array of channels where its research comes in very handy. Many Biotech companies are releasing new medications; DNAG is improving the effectiveness of drugs currently in research and on the market.

In an ever-evolving industry, biotech companies can be pigeon-holed by their research into a particular drug. We like DNAG because they have their fingers into so may different industries with a very versatile product. From crime labs to medical testing to the everyday consumer, DNAG can apply their research to essentially any forum. If DNAG’s valuable, avant-garde technology catches the attention of one of the industry giants, we are in for a great ride! And at a price where a meager $2500 investment buys you over 200,000 shares, it is definitely worth taking a chance. Think “risk-reward ratio”! You maximum loss is a penny, you maximum gain is…